NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 181 filers reported holding NEKTAR THERAPEUTICS in Q4 2015. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $41 | -14.6% | 57,901 | +170.4% | 0.00% | – |
Q4 2022 | $48 | -99.9% | 21,414 | -19.8% | 0.00% | -100.0% |
Q3 2022 | $85,000 | -22.0% | 26,702 | -7.0% | 0.00% | 0.0% |
Q2 2022 | $109,000 | -47.6% | 28,703 | -25.6% | 0.00% | 0.0% |
Q1 2022 | $208,000 | -56.0% | 38,594 | +10.3% | 0.00% | -50.0% |
Q4 2021 | $473,000 | -8.9% | 34,985 | +21.0% | 0.00% | -33.3% |
Q3 2021 | $519,000 | +29.4% | 28,905 | +23.6% | 0.00% | +50.0% |
Q2 2021 | $401,000 | +1.0% | 23,379 | +17.7% | 0.00% | 0.0% |
Q1 2021 | $397,000 | +43.8% | 19,866 | +22.2% | 0.00% | 0.0% |
Q4 2020 | $276,000 | +64.3% | 16,258 | +60.3% | 0.00% | +100.0% |
Q3 2020 | $168,000 | -97.5% | 10,140 | -94.5% | 0.00% | -98.2% |
Q2 2019 | $6,602,000 | -9.7% | 185,560 | -14.7% | 0.06% | -11.3% |
Q1 2019 | $7,310,000 | -6.8% | 217,571 | -8.8% | 0.06% | -15.1% |
Q4 2018 | $7,841,000 | -64.2% | 238,545 | -33.7% | 0.07% | -52.3% |
Q3 2018 | $21,924,000 | +1276.3% | 359,653 | +1002.3% | 0.15% | +1430.0% |
Q2 2018 | $1,593,000 | -57.0% | 32,628 | -6.4% | 0.01% | -60.0% |
Q1 2018 | $3,706,000 | +15.9% | 34,874 | -34.9% | 0.02% | +19.0% |
Q4 2017 | $3,198,000 | +952.0% | 53,545 | +322.7% | 0.02% | +950.0% |
Q3 2017 | $304,000 | +28.3% | 12,666 | +4.5% | 0.00% | 0.0% |
Q2 2017 | $237,000 | -17.7% | 12,123 | -1.2% | 0.00% | 0.0% |
Q1 2017 | $288,000 | +90.7% | 12,272 | 0.0% | 0.00% | +100.0% |
Q4 2016 | $151,000 | -39.8% | 12,272 | -15.9% | 0.00% | -50.0% |
Q3 2016 | $251,000 | -4.9% | 14,598 | -21.4% | 0.00% | 0.0% |
Q2 2016 | $264,000 | +16.3% | 18,576 | +12.8% | 0.00% | 0.0% |
Q1 2016 | $227,000 | +11.3% | 16,473 | +35.8% | 0.00% | +100.0% |
Q4 2015 | $204,000 | +15.3% | 12,127 | -24.8% | 0.00% | 0.0% |
Q3 2015 | $177,000 | +181.0% | 16,126 | +222.8% | 0.00% | – |
Q2 2015 | $63,000 | +46.5% | 4,996 | +28.3% | 0.00% | – |
Q1 2015 | $43,000 | -28.3% | 3,893 | +1.0% | 0.00% | – |
Q4 2014 | $60,000 | +11.1% | 3,856 | -13.8% | 0.00% | – |
Q3 2014 | $54,000 | -5.3% | 4,473 | 0.0% | 0.00% | – |
Q2 2014 | $57,000 | +1.8% | 4,473 | -3.8% | 0.00% | -100.0% |
Q1 2014 | $56,000 | +19.1% | 4,652 | +13.3% | 0.00% | – |
Q4 2013 | $47,000 | -67.1% | 4,105 | -69.9% | 0.00% | -100.0% |
Q3 2013 | $143,000 | +66.3% | 13,645 | +83.0% | 0.00% | 0.0% |
Q2 2013 | $86,000 | – | 7,458 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
CM Management, LLC | 35,000 | $595,000 | 0.55% |
OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |